THIS ANNOUNCEMENT IS FOR INFORMATION ONLY AND IS NOT AN OFFER TO PURCHASE OR A SOLICITATION OF OFFERS TO SELL ANY SECURITIES. Montrouge 9 September 2025 Crédit Agricole S.A. Announces Results of its Tender Offer for USD Perpetual Notes ____________________ Crédit Agricole S.A. (the “Company”) today announced the results of its offer launched on 2 September 2025 to purchase for cash any and all of its outstanding USD 8.125% Undated Deeply Subordinated Additional Tier 1 Fixed Rate Resettable Notes (the “USD ...

Outstanding value creation through at market merger of equalsAnglo Teck is expected to offer more than 70% copper exposure1 and outstanding further growth optionality embeddedUS$800 million in pre-tax recurring annual synergies from combining both companiesAdditional US$1.4 billion (100% basis) annual average underlying EBITDA uplift expected from synergies between the adjacent Collahuasi and Quebrada Blanca operations on an average pre-tax annual basis from 2030 - 2049, which is expected to result in an in ...

CGTN published an article highlighting China's call for BRICS countries to defend multilateralism. It outlines President Xi Jinping's proposals on multilateralism, openness and cooperation at the Virtual BRICS Summit. It also underscores the Global Governance Initiative as a roadmap for fairer global governance, with international support. BEIJING, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Over the past decade, the BRICS New Development Bank (NDB) has financed over 100 projects across infrastructure, clean energy ...

Core Viewpoint - Exosens has launched its 5G image intensifier tube, which significantly enhances night vision capabilities, offering a 30% improvement in overall performance (FOM) and up to a 35% increase in detection ranges compared to current standard tubes [1][7]. Company Overview - Exosens is a high-tech company with over 85 years of experience in the innovation, development, manufacturing, and sale of high-end electro-optical technologies, including amplification, detection, and imaging solutions [6][8]. - The company is listed on Euronext Paris and is part of several indices, including SBF 120 and CAC Mid 60, indicating its strong market presence [8]. Product Features - The 5G image intensifier tube offers unparalleled visual comfort, with sharper images and reduced noise or flicker, particularly in low-light conditions, enhancing the perception of textures, contrasts, and depth [2]. - The design and manufacturing of the 5G tubes are a French industrial achievement, contributing to the modernization of European armed forces [4]. Market Demand and Adoption - The ongoing conflict in Ukraine has highlighted the need for modernized equipment among European land forces, positioning the 5G technology as a preferred choice for special forces and a future standard for night vision [3]. - Exosens has already received orders for over 5,000 tubes prior to the official launch, indicating strong market demand and commercial success [5][7]. Strategic Positioning - Exosens aims to consolidate its position as a global leader in the night vision sector, with the 5G technology providing a tactical advantage in military operations [5][7]. - The company is set to be the only supplier capable of delivering this advanced technology to NATO members and allies, differentiating itself from U.S. solutions that are primarily available in the domestic market [7].

Core Insights - HMS Networks AB has set new financial and sustainability targets, which will be presented alongside the 2030 strategy and a business update at the Capital Markets Day [1][11] - The strategic period from 2020 to 2025 is nearing its end, with HMS on track to meet its 2025 targets established in 2020 [1] Financial and Business Strategy - From 2026 to 2030, HMS aims to accelerate customer acquisition and expand within its existing customer base, prioritizing mergers and acquisitions to strengthen each division [2] - Significant investments will be made in an updated product portfolio to enhance service offerings and increase annual recurring revenue (ARR) [2] - HMS has set a target for net sales of SEK 7.5 billion by 2030, with an EBITA margin target of 25% [7] - The company plans to grow ARR to 10% of net sales, contributing to a gross margin ambition of over 65% [7] Operational Performance - The business climate in Q3 has shown slight improvement in demand from the USA and Germany, while other EU markets and Japan have been weaker [4] - A temporary delivery stop in June due to a new ERP system has resulted in postponed deliveries of SEK 15 million, which are expected to be fulfilled in Q3 [5] - US tariffs negatively impacted gross margins in Q2, but price increases have offset this effect, leading to a slight improvement in gross margin [5] Sustainability and Employee Engagement - HMS is applying for the Science-Based Targets Initiative, aiming for a net positive carbon footprint by 2050 and an EcoVadis Gold rating [7] - The company has set an Employee Engagement Index target of 80 and aims to increase the share of female managers to at least 30% by 2030 [7] - The target for Customer Net Promoter Score is set at a minimum of 50 over the period [7] Financial Health - HMS is reducing its debt level month by month, with a goal to reach a net debt to EBITDA ratio of around 2.5x by year-end [6]

BW Energy: Completes Maromba FPSO financing and signs short-term lease for the development rig BW Energy is pleased to announce the completion of a USD 365 million project finance facility, backed by China Export & Credit Insurance Corporation (“Sinosure”), to fund the refurbishment and redeployment of the Maromba Floating Production Storage Offloading vessel (“FPSO”) to the Maromba field offshore Brazil. Separately, the Company finalised a short-term lease with Minsheng Financial Leasing Co., Ltd (“MSFL”) ...

Group 1 - Sampo plc announced a share buyback program with a maximum limit of EUR 200 million, which commenced on 7 August 2025 [1][2] - On 8 September 2025, Sampo plc acquired a total of 330,125 A shares at an average price of EUR 9.77 per share [1] - Following the transactions, Sampo plc holds a total of 7,558,217 A shares, representing 0.28% of the total shares outstanding [2] Group 2 - The share buyback program is in compliance with the Market Abuse Regulation (EU) 596/2014 and the Commission Delegated Regulation (EU) 2016/1052 [1] - The authorization for the buyback program was granted during Sampo's Annual General Meeting on 23 April 2025 [1]

Core Insights - BHP Xplor has opened applications for its 2026 cohort, continuing its mission to transform the discovery of critical minerals [1][4] - The program aims to support early-stage explorers with funding, mentorship, and access to BHP's extensive network [2][3] Group 1: Program Overview - BHP Xplor is a nine-month accelerator program designed to enhance exploration opportunities for participants [2] - The program offers up to USD $500,000 in equity-free funding, expert mentorship, and connections to BHP's global suppliers and service providers [2] - The 2026 cohort will join an alumni network of 21 companies, facilitating ongoing collaboration and knowledge sharing [2] Group 2: Industry Context - The demand for critical minerals is increasing, necessitating strong partnerships between major companies and junior explorers [2] - BHP Xplor is positioned as a key pathway for early-stage explorers to scale their operations and access vital resources [2][3] - Participation in the program has proven beneficial for companies, providing access to expertise and resources that accelerate project development [3]

Core Viewpoint - Novartis is set to acquire Tourmaline Bio for $48.00 per share, totaling approximately $1.4 billion, reflecting a significant premium over Tourmaline's recent stock prices, indicating strong confidence in Tourmaline's lead asset, pacibekitug, for treating cardiovascular diseases [1][2][3]. Transaction Details - The acquisition will be executed through a tender offer for all outstanding shares of Tourmaline at $48.00 per share in cash, representing a 59% premium to the closing stock price on September 8, 2025, and a 127% premium to the 60-day volume-weighted average stock price [1][3]. - The transaction has received unanimous approval from the Boards of Directors of both Novartis and Tourmaline and is expected to close in the fourth quarter of 2025, pending customary closing conditions [1][4]. Company Insights - Tourmaline Bio is a late-stage clinical biotechnology company focused on developing transformative medicines for inflammatory and immune diseases, with pacibekitug as its lead asset [6][7]. - Pacibekitug is a long-acting, fully-human, anti-IL-6 monoclonal antibody with potential best-in-class properties, having been studied in approximately 450 participants across six clinical trials [5][6]. Strategic Implications - The acquisition aligns with Novartis's commitment to innovation in cardiovascular care, as pacibekitug targets inflammation, a key driver of cardiovascular diseases, and addresses a significant unmet medical need in anti-inflammatory therapies [2][5]. - Novartis aims to leverage Tourmaline's expertise and accelerate the development of pacibekitug, enhancing its portfolio in cardiovascular treatment [2][4].

EfTEN Real Estate Fund AS earned consolidated rental income of EUR 2,704 thousand in August 2025, which is EUR 15 thousand more than in July. The increase in rental income was primarily due to the commencement of rental income of the new wing of the Ermi care home. The fund’s consolidated net rental income (NOI) in August amounted to EUR 2,622 thousand, up by EUR 18 thousand compared to July. During the first eight months of 2025, the fund earned total consolidated rental income of EUR 20.97 million, which ...